A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-15

Study Completion Date

2024-12-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of oral AZD6793 in healthy Japanese and Chinese participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants

NCT06502379

Healthy Participants

COMPLETED PHASE1

Study to Assess Safety, Tolerability and Pharmacokinetics After Single and Multiple Doses of AZD1446 to Japanese Subject

NCT01021189

Healthy

COMPLETED PHASE1

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Modified-Release Formulations of AZD1446 After Oral Single and Repeated Doses

NCT01199315

Healthy

COMPLETED PHASE1

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 in Healthy Japanese and Chinese Participants.

NCT06519968

Healthy Participants

COMPLETED PHASE1

AZD7268 Single Ascending Dose Study in Healthy Japanese Subjects

NCT00912353

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be conducted to assess the safety, tolerability, and PK of oral AZD6793 suspension following single (Part 1) and multiple (Part 2) administrations in healthy Japanese and Chinese participants performed at a single Clinical Unit.

Part 1 of the study will comprise:

* A Screening Period of maximum 28 days (Day -29 to Day -2).
* A Treatment Period during which participants will be resident at the Clinical Unit from Day -1 until at least 72 hours after study intervention administration.
* A Follow-up Visit within 6 ± 1 days after the study intervention administration.

Part 2 of the study will comprise:

* A Screening Period of maximum 28 days (Day -29 to Day -2).
* A Treatment Period during which participants will be resident at the Clinical Unit from Day -1 (the day before first study intervention administration \[Day 1\]) until Day 10.
* A Follow-up Visit within 6 ± 1 days after the last study intervention administration.

Participants will be randomized to receive AZD6793 and placebo in both Part 1 and Part 2.

Participants who enrolled in Part 1 will be excluded from participation in Part 2 of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Participants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part 1: Cohort 1 AZD6793

6 Healthy Japanese participants will receive single dose of AZD6793 dose 1 and 2 healthy Japanese participants will receive matching placebo to AZD6793 as oral suspension on Day 1.

Group Type EXPERIMENTAL

AZD6793

Intervention Type DRUG

Participants will receive AZD6793 single dose as oral suspension.

Placebo

Intervention Type DRUG

Participants will receive matching doses of placebo as oral suspension.

Part 1: Cohort 2 AZD6793

6 Healthy Japanese participants will receive single dose of AZD6793 dose 2 and 2 healthy Japanese participants will receive matching placebo to AZD6793 as oral suspension on Day 1.

Group Type EXPERIMENTAL

AZD6793

Intervention Type DRUG

Participants will receive AZD6793 single dose as oral suspension.

Placebo

Intervention Type DRUG

Participants will receive matching doses of placebo as oral suspension.

Part 1: Cohort 3 AZD6793

6 Healthy Chinese participants will receive single dose of AZD6793 dose 1 and 2 healthy Chinese participants will receive matching placebo to AZD6793 as oral suspension on Day 1.

Group Type EXPERIMENTAL

AZD6793

Intervention Type DRUG

Participants will receive AZD6793 single dose as oral suspension.

Placebo

Intervention Type DRUG

Participants will receive matching doses of placebo as oral suspension.

Part 2: Cohort 1 AZD6793

6 Japanese participants will receive single dose of AZD6793 and 2 participants will receive matching placebo on Day 1. After a washout of at least 48 hours, participants will receive AZD6793 or placebo once daily from Day 3 to Day 8.

Group Type EXPERIMENTAL

AZD6793

Intervention Type DRUG

Participants will receive AZD6793 multiple doses daily as oral suspension.

Placebo

Intervention Type DRUG

Participants will receive matching doses of placebo as oral suspension.

Part 2: Cohort 2 AZD6793

6 Chinese participants will receive single dose of AZD6793 and 2 participants will receive matching placebo on Day 1. After a washout of at least 48 hours, participants will receive AZD6793 or placebo once daily from Day 3 to Day 8.

Group Type EXPERIMENTAL

AZD6793

Intervention Type DRUG

Participants will receive AZD6793 multiple doses daily as oral suspension.

Placebo

Intervention Type DRUG

Participants will receive matching doses of placebo as oral suspension.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD6793

Participants will receive AZD6793 single dose as oral suspension.

Intervention Type DRUG

AZD6793

Participants will receive AZD6793 multiple doses daily as oral suspension.

Intervention Type DRUG

Placebo

Participants will receive matching doses of placebo as oral suspension.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. For Japanese participants only:

1. Participant was born in Japan
2. Participant has 2 Japanese biological parents and 4 Japanese grandparents as confirmed by the interview.
3. Participant did not live outside of Japan for more than 10 years at the time of the Screening Visit.
2. For Chinese participants only:

1. Participant was born in China (including Hong Kong, Macau, and Taiwan)
2. Participant has 2 Chinese biological parents and 4 Chinese grandparents as confirmed by the interview.
3. Participant did not live outside of greater China for more than 10 years at the time of the Screening Visit.
3. All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.
4. Females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception,
5. Have a body mass index between 18 and 30 kilograms per meter square (kg/m2) inclusive and weigh at least 45 kilograms (kg), at the Screening Visit.
6. Females of non-childbearing potential must be confirmed at the screening Visit by fulfilling one of the following criteria:

1. Postmenopausal defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and FSH levels in the postmenopausal range.
2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy (but not tubal ligation).

Exclusion Criteria

1\. History of any clinically important disease or disorder or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.

3\. Diagnosis or history of immunodeficiency or increased susceptibility to severe infection, or a clinically significant infection within 4 weeks of the Screening Visit.

4\. Any positive result on screening for serum hepatitis B surface antigen, hepatitis B core antibody, or human immunodeficiency virus.

5\. History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD6793.

6\. Plasma donation within one month of the Screening Visit or any blood donation/blood loss greater than (\>) 500 milliliter (mL) during the 3 months prior to the Screening Visit.

7\. Participants who have previously received AZD6793. 8. Positive or indeterminate QuantiFERON® TB test at Screening Visit. 9. Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the previous 3 months prior to the Screening Visit.

10\. Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as judged by the Investigator.

11\. Positive screen for drugs of abuse, or alcohol or cotinine at the Screening Visit or admission to the Clinical Unit (Day -1).

12\. Excessive intake of caffeine-containing drinks or food (eg, coffee, tea, chocolate) defined as the regular consumption of more than 500 mg of caffeine per day (eg, \> 5 cups of coffee \[one cup \~100 mg caffeine\]; one cup of tea \~30 mg caffeine).

13\. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of study intervention.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes